Zafgen has something to cheer as diabetes drug makes the cut in PhII study
After being plagued by a laundry list of setbacks that culminated in the desertion of its obesity drug and the departure of its CEO, Zafgen …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
